Protocol Ledger

NCT06320067 · Phase III · RECRUITING

A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer

Interventional Phase III clinical trial protocol NCT06320067 sponsored by University College, London in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-06-11 Enrollment: 3,360 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06320067
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)3,360 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06320067
Protocol FieldVerified Registry Value
NCT IdentifierNCT06320067
Consolidated Lead SponsorUniversity College, London
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment3,360 participants (ESTIMATED)
Registered Start Date2024-06-11
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06320067
Hospital Research SiteLocationSite Profile
University College London Hospitals NHS Foundation TrustLondon, United KingdomOpen Hospital Dossier ->
Barts Health NHS TrustLondon, United KingdomOpen Hospital Dossier ->
Royal Free HospitalLondon, United KingdomOpen Hospital Dossier ->
Churchill HospitalOxford, United KingdomOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI